Title : Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.

Pub. Date : 2022 Feb

PMID : 34862655






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Compounds 18, 13, and 10 were more potent than sorafenib, inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2) at GI50 values of 0.05, 0.06, and 0.08 microM, respectively. Sorafenib kinase insert domain receptor Homo sapiens
2 Compounds 18, 13, and 10 were more potent than sorafenib, inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2) at GI50 values of 0.05, 0.06, and 0.08 microM, respectively. Sorafenib kinase insert domain receptor Homo sapiens
3 Compound 11 inhibited VEGFR-2 at an IC50 value of 0.10 microM, which is equipotent to sorafenib. Sorafenib kinase insert domain receptor Homo sapiens
4 Compound 14 inhibited VEGFR-2 at an IC50 value of 0.11 microM, which is nearly equipotent to sorafenib. Sorafenib kinase insert domain receptor Homo sapiens